Sarepta Stock Drops Amid FDA Elevidys Comments
FDA Faces Scrutiny Over Elevidys Approval amid Safety Concerns and Executive overruling
Table of Contents
The U.S. Food and Drug Governance (FDA) is under intense scrutiny following its expanded approval of Sarepta Therapeutics‘ Duchenne muscular dystrophy gene therapy, Elevidys.Reports indicate that FDA leadership, including Dr. Peter Marks, overruled agency staff recommendations, a decision now shadowed by recent patient deaths and heightened safety concerns.
Elevidys Approval: A Controversial Decision
The FDA’s decision to expand the approval of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), has ignited a firestorm of debate. While Sarepta Therapeutics hailed the expanded approval as a significant step forward for patients, critics point to a series of concerning events that have cast a dark cloud over the therapy’s safety profile.
Sources familiar with the matter revealed that Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, ultimately agreed with Sarepta’s assessment and overruled FDA staff who had expressed reservations. This move has raised questions about the agency’s decision-making process and its commitment to rigorous safety standards.
Safety Alarms Sounded: Patient Deaths and Delivery Method Concerns
The controversy surrounding Elevidys intensified earlier this year when Sarepta disclosed that two teenage boys died from liver failure after receiving the gene therapy. These tragic events have amplified existing safety concerns, especially given that another patient died during a Phase 1 trial investigating a different Sarepta gene therapy for a separate disease.While the two therapies are distinct, they share the same method of delivery. This commonality has heightened anxieties about the potential risks associated with Elevidys. Analysts, such as Kostas Biliouris of BMO, have emphasized the critical importance of addressing these safety risks, especially in light of what he describes as the “uncertain benefit” of the treatment.
Biliouris drew a parallel to Novartis’ gene therapy Zolgensma for spinal muscular atrophy, which has also been associated with liver toxicity and fatalities. However, he noted that Zolgensma’s therapeutic benefit is clearly established, making the deaths in the context of Elevidys particularly concerning. “That’s why deaths here matter so much versus Zolgensma,for example,” Biliouris stated.
Sarepta’s Reliance on Elevidys and Investor Concerns
For Sarepta Therapeutics,Elevidys represents a significant portion of its future revenue. Unlike large pharmaceutical companies with diverse portfolios, Elevidys is crucial to Sarepta’s financial stability. Executives have attempted to reassure investors, projecting that the therapy could generate at least $500 million annually, even if it is indeed restricted to treating patients who can still walk, a group where no deaths have been reported.
In a move to address safety concerns, Sarepta recently halted shipments of Elevidys to patients who can no longer walk, while it investigates a safer administration method.However, the primary concern for investors remains the possibility of the FDA withdrawing the drug from the market. The company’s stock has already experienced a dramatic decline, falling more than 87% this year. “If the FDA pulls Elevidys from the market,” Biliouris warned, ”Sarepta is done.”
A Parent’s Perspective: The Dilemma of Limited Options
The potential pause or withdrawal of Elevidys presents a heartbreaking dilemma for families affected by Duchenne muscular dystrophy. Jennifer Handt, whose son Charlie was diagnosed with the condition in late 2020, expressed her distress at the prospect of other patients losing a treatment option.
Charlie received elevidys in 2022 as part of Sarepta’s late-stage trial and showed notable improvements, including increased stamina and more fluid movements. The therapy also eased a key symptom of DMD known as Gowers’ sign. Handt reported that her son has remained “completely stable” three years post-treatment and was aware of the liver toxicity risks before enrolling him in the trial.
“We don’t have the luxury of not taking the risk,” Handt stated, emphasizing the desperate need for treatment options for families facing this debilitating disease. ”There are families that dealt with this disease before that woudl have done anything to have an option, even if there are risks.” She concluded,”Every family should have the choice to take this leap with this drug and potentially see benefits.”
The unfolding situation with Elevidys highlights the complex and frequently enough fraught balance between therapeutic innovation, patient access, and rigorous safety oversight within the pharmaceutical industry. The FDA’s decision and the subsequent events will undoubtedly shape future regulatory approaches to gene therapies.